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Abstract
Background: Recently, much attention has been focused on gaining a better understanding of the different
populations of cells within a tumor and their contribution to cancer progression. One of the most commonly used
methods to isolate a more aggressive sub-population of cells utilizes cell sorting based on expression of certain
cell adhesion molecules. A recently established method we developed is to isolate these more aggressive cells
based on their properties of increased invasive ability. These more invasive cells have been previously characterized
as tumor initiating cells (TICs) that have a stem-like genomic signature and express a number of stem cell genes
including Oct3/4 and Nanog and are more tumorigenic compared to their ‘non-invasive’ counterpart. They also
have a profile reminiscent of cells undergoing a classic pattern of epithelial to mesenchymal transition or EMT.
Using this model of invasion, we sought to investigate which genes are under epigenetic control in this rare
population of cells. Epigenetic modifications, specifically DNA methylation, are key events regulating the process of
normal human development. To determine the specific methylation pattern in these invasive prostate cells, and if
any developmental genes were being differentially regulated, we analyzed differences in global CpG promoter
methylation.
Results: Differentially methylated genes were determined and select genes were chosen for additional analyses.
The non-receptor tyrosine kinase BMX and transcription factor SOX1 were found to play a significant role in
invasion. Ingenuity pathway analysis revealed the methylated gene list frequently displayed genes from the IL-6/
STAT3 pathway. Cells which have decreased levels of the targets BMX and SOX1 also display loss of STAT3 activity.
Finally, using Oncomine, it was determined that more aggressive metastatic prostate cancers in humans also have
higher levels of both Stat3 and Sox1.
Conclusions: Using this method we can begin to understand which genes are epigenetically regulated in the
invasive population compared to the bulk tumor cells. These aggressive sub-populations of cells may be linked to
the cancer stem cell hypothesis, making their patterns of epigenetic regulation very attractive for biomarker
analysis.
Background
Cancer is defined as uncontrolled cell growth resulting
from genetic mutations or exposure to environmental
carcinogens that alter normal regulation. If the cancer is
aggressive in nature, invasion of local tissues near the pri-
mary tumor site as well as distant metastasis can occur.
Current treatment regimens almost always involve a
form of surgery to remove the primary tumor and
systemic chemotherapy with localized radiation. How-
ever, aggressive cells can remain in the body and evade
treatment with these conventional therapies. Addition-
ally, it has been well documented that only a small frac-
tion of epithelial tumor cells have the ability to form
colonies in vitro or to initiate a new tumor upon injection
into a host in vivo [1-6]. In order to study the epigenetic
regulation of these aggressive cells, we chose to study an
invasive population of prostate cancer cells. We and
others have developed a novel method for the isolation of
these cells from bulk tumor cell populations using Matri-
gel [7,8]. These cells have a stem-like phenotype [7] and
exist within both established cell lines (LNCaP and
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cer tissue (PCSC1-3). The invasive cells have been char-
acterized as undergoing an epithelial to mesenchymal
transition (EMT) during the process of invasion, and are
also highly tumorigenic when injected into mice [7].
They demonstrate increases in the stem cell regulators
CD44, CD133, Bmi1, Nanog,a n dSonic hedgehog (Shh),
as well as increased expression in mesenchymal markers
such as Vimentin and Tgfb-1, and a decrease in the
epithelial marker E-cadherin (CDH1). Over the last few
years this hypothesis of EMT and cancer progression has
been widely supported in models of not only prostate
cancer, but also within the breast, colon, lung and pan-
creas [9-16]. The idea that the same cells which are
u n d e r g o i n gt h eE M Tm a ya l s ob eap o p u l a t i o no fc e l l s
called cancer stem cells or CSCs is a relativity new
concept.
I ti sb e c o m i n gm o r ee v i d e n tt h a tC S C sa r en o tg o v -
erned by the same type of genetic regulation as normal
stem cells, and arguably in solid tumors may be an
epithelial cell that has up-regulated pathways that have
been previously observed in true stem cells. In order to
determine the epigenetic profile of these invasive pros-
tate cancer cells, we isolated DNA and performed a very
sensitive MeDIP (methylated DNA immunoprecipita-
tion) assay coupled with Agilent’s 244 K Human Promo-
ter Tiling Arrays. This allowed for an in-depth analysis
of the methylation status within promoter elements,
upstream as well as down, in these cells. Differences
between the invaded (more stem-like) and non-invaded
cells, as well as the bulk tumor cell line (parental cells)
were compared. In our analysis, the LNCaP and DU145
cell lines were used, as well as confirmation analysis in
two primary prostate cancer cell lines (PCSC1 and
PCSC2).
A unique set of genes were found to be expressed in
the invasive cells, yet methylated in the non-invasive
cells and parental cell lines. This included genes
involved in embryonic and tissue/organ development,
and specifically in neurogenesis including bone marrow
X kinase (Bmx), Iroquois homeobox 3 (Irx3), Sine oculis
homeobox homolog 1 (Six1) and Sex determining
region-Y-box 1 (Sox1). Using the available online
expression databases in Oncomine, it was determined
that Sox1 plays a significant role in prostate cancer pro-
gression and metastasis. Furthermore, Ingenuity pathway
analysis determined that the set of differentially methy-
lated genes are involved in cellular functions such as
cell-to-cell interaction and cell morphology, as well as
development of the hematological system and cancer.
The most intriguing data identified many of the methy-
lated targets as members of the IL-6/STAT3 signaling
pathway. Further investigation demonstrated that Stat3
was increased in these invasive cells, and cells infected
with an shRNA against either BMX or SOX1 resulted in
decreased levels of activated STAT3. However, only the
differentially methylated Sox1 directly interacts with
STAT3. Thus, in our model SOX1 plays a critical role
in regulating invasive prostate cancer cells. These
aggressive sub-populations of cells may be linked to the
cancer stem cell hypothesis, making their patterns of
epigenetic regulation very attractive for biomarker
analysis.
Materials and methods
Cell Lines and Reagents
LNCaP and DU145 human prostate cancer cell lines
were obtained from ATCC and cultured accordingly
(Manassas, VA). Primary human prostate cancer cells
(PCSC1-2) [7] were acquired from Celprogen (San
Pedro, CA) and maintained as recommended using spe-
cific coated culture plates and defined media. Human
bone marrow derived mesenchymal stem cells (hMSCs)
w e r eo b t a i n e df r o mL o n z a( G a i t h e r s b u r g ,M D )a n d
maintained using their recommended conditions. The
cultures were maintained in 5% CO2 air at 37°C.
Human serum was obtained from Gemini Bioproducts
(West Sacramento, CA). The following inhibitors were
also used: Anti-human IL-6 antibody (R&D Systems,
Minneapolis, MN), PI3K inhibitor LY294002 (Cell Sig-
n a l i n g ,D a n v e r s ,M A ) ,T e cK i n a s ei n h i b i t o rL F M - A 1 3
(Tocris, Ellisville, MO), MEK inhibitor PD98059 (Gibco,
Carlsbad, CA), JAK inhibitor AG490 (Gibco), and
STAT3 inhibitor Stattic (Sigma Aldrich, St. Louis, MO).
Matrigel Invasion Assay
Matrigel-coated 24-well inserts (8 μM pore size) and
non-coated control inserts purchased from BD Bios-
ciences (Palo Alto, CA) were used according to manufac-
turer’s instructions. A range of 20,000-100,000 cells were
seeded for the invasion (higher for less invasive LNCaP
cells). Cells were seeded in serum-free RPMI and
migrated toward media specific for stem cells (SCM)
containing DMEM/F12 with human supplementation of
10 ng/mL bFGF, 20 ng/mL EGF and 5 μg/mL insulin
along with 0.4% BSA (each from Sigma, St. Louis, MO).
Routine invasion assays were performed for 24 hours and
then stained with the Diffi-Quick Staining kit (Dade
Behring, Deerfield, IL). Three to five microscopic fields
(20×) were photographed and counted for each sample.
Percent invasion was calculated as average number of
cells/field (Matrigel) divided by average number of cells/
field (control insert). Values were averaged from 2-5 inde-
pendent experiments. For the isolation of cells from top
‘non-invading’ and bottom ‘invading’ cells, parallel inva-
sion chambers were setup. For non-invading cells, the
bottom of the membrane was scrubbed with a cotton
swab and cells on top were harvested using 500 μLo f
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for 5 minutes. To obtain the invading cells, the top of the
membrane was scrubbed with a cotton swab and the
chambers were placed into another 24- well plate con-
taining 500 μL of Accutase incubated at 37°C for
5 minutes.
MeDIP Arrays
Matrigel invasion assays were carried out as previously
described. For the isolation of DNA from both non-inva-
sive and invasive cells the DNeasy kit from Qiagen
(Valencia, CA) was used and parallel invasion chambers
were setup. For non-invading cells, the bottom of the
membrane was scrubbed with a cotton swab and cells on
top were trypsinized and harvested in 200 μLo fP B Sf o l -
lowed by the direct addition of lysis buffer or stored at
-80°C. For bottom ‘invading cells’ the top of the mem-
brane was scrubbed with a cotton swab and the mem-
brane was removed and placed directly into lysis buffer
or stored at -80°C until needed. A modified version of
Agilent’s (Santa Clara, CA) protocol for Mammalian
ChIP on ChIP was used to capture methylated DNA with
immunoprecipitation (MeDIP). DNA was quantified and
2 μg (or total yield if less) was digested with MseI over-
n i g h ta t3 7 ° C .L i n k e r s( J W 1 0 2 - 5 ’-GCGGTGACCCGG-
GAGATCTGAATTC-3’ and JW103-5’-TAGAATTCAG
ATC-3’) were ligated at 16°C using T4 ligase overnight
and the next day used as input for the MethylCollector
(Active Motif, Carlsbard, CA) assay to isolate methylated
and non-methylated fractions of DNA. The kit utilizes
histidine-tagged MeBP2 (methyl-binding protein 2) and
magnetic bead separation. The isolated methylated and
non-methylated DNA from each sample (as little as 5 ng)
was then amplified in a series of PCR reactions following
the mammalian ChIP on ChIP protocol. The input DNA
was labeled with Cy3-dUTP and the methylated DNA
with Cy5-dUTP and then immediately applied to Agi-
lent’s 2 × 244 K Human Promoter Tiling Arrays for 40
hours at 65°C. The arrays were scanned using a Gene Pix
4000B scanner (Molecular Devices, Sunnyvale, CA) with
GenePix Pro software version 6.1 and extracted using
Agilent’s Feature Extraction software version 9.5.3.1. The
data was annotated using Agilent’sC h I PA n a l y t i c ss o f t -
ware version 4.0. Normalization was carried out using a
blank subtraction model and statistical stringency
(p-value) between 0.01-0.05 was applied using a White-
head Per-Array Neighbourhood Analysis. This analysis
allowed for the determination of differentially methylated
genes between non-invasive and invasive cells. Ingenuity
core analysis was carried out to determine which path-
ways are of functional significance based on the gene lists
identified http://www.ingenuity.com/. Genomatix soft-
ware was used to determine transcription factor binding
sites (matrix). A perfect match to the matrix gets a score
of 1.00 (each sequence position corresponds to the high-
est conserved nucleotide at that position in the matrix),
a “good” match to the matrix usually has a similarity
of >0.80.
Mismatches in highly conserved positions of the
matrix decrease the matrix similarity more than mis-
matches in less conserved regions.
Methylation Specific polymerase chain reaction (MSP-PCR)
A total of 1 μg of DNA extracted from total (parental)
DU145 and LNCaP cells was bisulfite modified using
the EpiTect Bisulfite kit from Qiagen. PCR was per-
formed using Platinum Taq Polymerase (Invitrogen) and
200 ng of either genomic or bisulfite treated DNA. The
PCR method utilized was 94°C for 2 minutes, then 35
cycles (94°C for 30 seconds, 55°C for 30 seconds and
72°C for 1 minute) with a final extension of 10 minutes
at 72°C. The unmethylated primers however were run
with an annealing temperature of 42°C since their melt-
ing temperature values were drastically different from
their methylated counter part. A portion of the PCR
product was run on a 1% agarose gel containing ethi-
dum bromide.
Methylated primers
hBMX-Forward 5’- TGGTGAGACATCATGTGTTC-
CATT-3’;
hBMX-Reverse 5’- ATGCCCTCAGTTGAGAAC-
CACTGT-3’;
hSOX1-Forward 5’-ATGATCAGCATGTACTTGC
CCGC-3’;
hSOX1- Reverse 5’-TCCGCTTCCTCCGTAGGTGA-
TAAA-3’
Unmethylated primers
hBMX-Forward 5’- TGGTGAGATATTATGTGTTT-
TATT-3’;
hBMX-Reverse 5’- ATGTTTTTAGTTGAGAAT-
TATTGT-3’;
hSOX1-Forward 5’-ATGATTAGTATGTATTTG
TTTGT-3’;
hSOX1-Reverse 5’-TTTGTTTTTTTTGTAGGTGA-
TAAA-3’
Quantitative real time polymerase chain reaction (QRT-
PCR)
Total RNA was isolated using TRIzol (Invitrogen Corpora-
tion, Carlsbad, CA). RNA from ‘top’ cells was isolated
using a cell pellet acquired from trypsinizing cells from
one membrane after bottom cells were removed with a
cotton swab. Conversely, RNA from the bottom cells was
isolated by combining three membranes where the top
cells were removed using a cotton swab. The membranes
were pooled and placed in TRIzol for 10 minutes at room
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of RNA was then followed. To increase the yield of RNA,
5 μg of linear acrylamide (Ambion, Austin, TX) was added
prior to precipitation of RNA with isopropanol. Addition-
ally to increase overall yield, 100 ng of RNA was amplified
using the MessageAmp aRNA Amplification Kit (Ambion,
Austin, TX). cDNA was prepared using the SuperScript®III
First-Strand Synthesis System (Invitrogen Corporation,
Carlsbad, CA). Quantitative real time polymerase chain
reaction (qRT-PCR) analysis was performed using a
StepOne Real-time PCR machine (Applied Biosystems,
Foster City, CA) with TaqMan Gene Expression Assay
reagents and probes (Applied Biosystems). A total of 4 μL
of cDNA was used in a 20 μL reaction resulting in a 1:5
dilution. The following FAM labeld human probes were
used: BMX (Hs00174139_m1), IRX3 (Hs00273561_s1),
SOX1 (Hs01023894_m1), MCL-1 (Hs00172036_m1),
MYC (Hs00153408_m1), STAT3 (Hs01047580_m1), SUR-
VIVIN (Hs00977611_g1) and 18S rRNA (Hs99999901_s1).
Relative fold induction of mRNA was compared between
non-invasive and invasive cells using the Delta-Delta CT
method of quantitation, and 18S rRNA was used as a load-
ing control.
shRNA of Bmx and Sox1
The Trans-Lentiviral pTRIPZ system from Open Biosys-
tems (Huntsville, AL) was used to introduce shRNA
against BMX (Clone ID: V2THS_150067) and SOX1
(V2THS_197330) along with a non-silencing control
vector. The vectors were transfected into HEK239T cells
which were seeded in serum-free media at 60% con-
fluency in 10 cm
2 dishes using the Arrest-In reagent
provided in the kit. The cells were transfected for 6
hours and then replaced with complete media. After 24
and 48 hours lentiviral supernatants were harvested,
spun at 1500 rpms, and filtered using a 0.45 μM filter to
clear them. The viral titer was mixed 1:1 with DU145
media and placed on sub-confluent DU145 cells for 4-6
hours and changed to complete media. The next day
media containing 1 μg/mL of doxycycline (Sigma) was
added to ensure efficient transfection/infection has
occurred. Efficient transfection was observed using a
TET inducible TurboRFP (red fluorescent protein)
upstream of the shRNA that appears red upon success-
ful infection. The cells were selected for 2 weeks in 1
μg/mL of puromycin (Sigma). Single cell clones were
then generated and lowered expression was confirmed
using Western blotting.
Western Blotting and sub-cellular fractions
Total cell lysates were prepared using RIPA buffer
(Sigma) and sub-cellular fractions using the NE-PER
Nuclear Protein Extraction Kit (Thermo Scientific,
Rockford,IL). Samples were loaded onto a 4-20% Tris-
glycine gel and transferred to a PVDF membrane. The
membranes were blocked at room temperature for
45 minutes in 5% non-fat milk in TBS-Tween (0.05%).
Primary antibodies were as follows: BMX (Abcam-
59360), pBMX (Cell Signaling-3211S), STAT3 (Santa
Cruz-SC482), pSTAT3/Tyr705 (Cell Signaling-9131S),
SOX1 (Cell Signaling 4194S) and Actin (Abcam-8227-
50) and incubated overnight at 4°C. The membrane was
washed 3× for 10 minutes each using TBS-T (0.1%).
Secondary antibody was applied for 1 hour at room
temperature (infrared goat-anti rabbit or mouse in the
800 channel) and washed. The membrane was devel-
oped using the Odyssey from Licor (Lincoln, NE). Pro-
tein loading was normalized using actin as a control.
Densitometry analysis was performed using ImageJ
(NIH, Bethesda, MD).
Proliferation Assays
Cells were seeded overnight in a 96 well plate in 100 μL
of regular media at a density of 2000 cells per well. Cell
proliferation was measured using the CellTiter-Glo
assay from Promega on Day 1, 3, 5 and 7 using 100 μL
of reagent and an incubation time of 20 minutes. The
relative luciferase units (RLU) were quantified using a
Tecan Infinite 200 plate reader.
Prostatosphere Formation Assays
LNCaP and DU145 cells were seeded at 1000 cells per
mL in replacement media SCM supplemented with KO
Serum Replacement (Invitrogen) for LNCaP or B27
(Invitrogen) for DU145 cells in non-adherent 6 well
plates coated with Hydrogel (Corning Life Sciences,
Chemlsford, MA). The prostatospheres were generated
for 5-7 days and then quantified or RNA extracted.
Immunofluorescence
Staining of invasive or non-invasive cells was performed
directly on the Matrigel membrane. Duplicate invasion
chambers were used for each antibody; one each for stain-
ing invasive cells or non-invasive cells. Cells not being
stained were removed from each insert, and cells of inter-
est were fixed to the membrane in 4% para-formaldehyde
for 15 minutes at 25°C and permeabilized with 0.5% sapo-
nin in PBS for 15 minutes at 25°C followed by a series of
washes with PBS. Non-specific antibody binding sites were
blocked for 15 minutes with 1% BSA in PBS containing
0.1% Tween-20 (PBS-T). Cells were incubated with either
anti-pBMX antibody in PBS-T, SOX1 (Cell Signaling,
Danvers, MA), or pSTAT3 (Millipore/Upstate Technolo-
gies, Billerica, MA (4°C, overnight). Following 3× PBS-T
washes, infrared goat anti-rabbit Alexa 488 (Molecular
Probes, Carlsbad, CA) was added for 1 hour at 25°C
using a 1:500 dilution in PBS-T and again washed, then
air-dried. Membranes were mounted on glass slides with
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game, CA). Cells were visualized with a Zeiss-510 L5 con-
focal microscope where separate images were obtained for
Alexa-488 and DAPI fluorescence, as well as overlays and
10 slice Z-stacks. Images were analyzed using the Zeiss
LSM5 Image Browser (version 3.2.0.115) and further pre-
pared in Adobe Photoshop CS. “Non-invasive” cells were
stained on the topside of the membrane, while “invasive
cells” were stained on the underside of the membrane.
Controls using the secondary antibody and no primary
antibody indicated that little, if any, fluorescence was con-
tributed by non-specific binding of this antibody (data not
shown).
Immunoprecipitation
Protein was extracted using RIPA buffer (Sigma) and
lysates were incubated with either SOX1, STAT3 or
BMX (same antibodies used in Western Blotting) over-
n i g h ta t4 ° Cw i t hr o t a t i o n .T h en e x td a yP r o t e i nA
sepharose beads were added to the lysate and incubated
for 3 hours with rotation at 4°C. The lysate was then
spun at 13,000 rpms in a benchtop centrifuge and
washed 3× with RIPA buffer. Before loading on a 4-20%
Tris-Glycine SDS-Page gel (Invitrogen) 2× loading buffer
was added and upon completion the gel was transferred
to a PVDF membrane. The membrane was blocked for
45 minutes using 5% non-fat milk in TBS-T (0.1%). The
membrane was then incubated overnight at 4°C using
either primary antibodies SOX1 or STAT3 diluted in
blocking buffer to confirm a direction interaction. The
membrane was washed 3× for 10 minutes each using
TBS-T (0.1%). Secondary antibody was applied for
1 hour at room temperature (infrared goat-anti-rabbit in
the 800 channel) and washed. The membrane was devel-
oped using the Odyssey from Licor. Protein loading was
normalized using actin from pervious Westerns.
EMSA
The Licor EMSA buffer kit was used according to the
manufacturer’s instructions. Infrared (IR) and unlabeled
STAT3 oligos were ordered from IDT and used at 0.625
fmoles/reaction.
Wildtype probes (WT): (800-IR channel and unlabeled)
F- 5’-GATCCTTCTGGGAATTCCTAGATC-3’;
R- 5’-GATCTAGGAATTCCCAGAAGGATC-3’
Mutant probes (MU): (700-IR channel)
F- 5’-GATCCTTCTGGGCCGTCCTAGATC-3’;
R- 5’-GATCTAGGACGGCCCAGAAGGATC-3’;
Mutant oligos and unlabled wildtype oligos were used
at 200-fold molar excess. A total of 20 μg of nuclear
protein extract was incubated with 1× binding buffer
(100 mM Tris, 500 mM KCl, 10 mM DTT; pH 7.5),
Poly (dl·dC) 1 μg/μL (in 10 mM Tris, 1 mM EDTA, pH
7.5), 25 mM DTT/2.5% Tween-20, 1% NP-40, 100 mM
MgCl2, and 50% glycerol for 20 minutes at room tem-
perature shielded from light. For supershift experiments,
extracts were pre-incubated with 5 μgo fS T A T 3a n t i -
body at 4°C for 30 minutes. DNA/protein complexes
were visualized on a native 6% Tris-Borate-EDTA polya-
crylamide gel. Gels were immediately removed from cas-
settes and scanned using the Odyssey in both the 700
and 800 channels.
Meta-analysis on patient databases
Oncomine and Gene Expression Omnibus (GEO) data-
bases were queried to identify associations between
genes. GEO database is available at http://www.pubmed.
o r g( G E Op r o f i l e s )a n dp r o vides raw expression data
from several gene expression arrays. Oncomine 4.2 data-
base analysis tool is available with a subscription at
http://www.oncomine.org. Selected data was compared
for gene expression levels in prostate primary tumor
samples as well as their respective metastatic specimens.
Data have been selected from [17] because this study
was an integrated molecular profiling of gene expression
in prostate cancer samples. In this work, a significant
concordance between expression of Sox1 and Stat3
mRNA was found to correlate with the aggressiveness of
the sample.
Statistical Analysis
All statistical calculations were performed using Graph-
Pad Prism Version 5. Comparisons between groups
were carried out using either a Student’s pair-wise t-test,
or a One or Two-way ANOVA with a Bonferroni post-
test wherever each test was applicable. Error bars repre-
sent the Standard Error of the Mean (SEM) and each
experiment has been completed at least twice with
samples in triplicate.
Results
Identification of differentially methylated genes in
invasive sub-populations of cells
Individual promoter tiling arrays were performed to
analyze global CpG promoter methylation for both non-
invasive and invasive cell isolates from both LNCaP and
DU145 (Figure 1). The cells were allowed to invade the
Matrigel toward a highly defined media called stem cell
media (SCM) [18]. It was then determined which genes
were methylated in the non-invasive cells and not in the
invasive fraction of cells. This analysis determined that
869 probes were differentially methylated in the non-
invasive LNCaP fraction compared with the invasive and
1015 for DU145 (Additional File 1, Tables S1A and
S1B). A very small subset of 44 overlapping genes was
methylated in the non-invasive cells and not in the inva-
sive population from both of the prostate cancer lines
analyzed. These included genes involved in development
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dinase (Dio3), and an embryonic version of myosin
(Myh3) (Table 1). Using the Oncomine database we
investigated changes in expression patterns for these
methylated targets, and we found a significant associa-
tion between progression of prostate cancer and metas-
tasis with expression of a number of genes including G
protein, beta-1 subunit (Gnb1), retinoblastoma binding
protein 8 (rbbp8), secretogranin III (Scg3)a n dSox1
(Figure 2). Albeit a number of these proteins have been
shown to play a role in cancer, we chose to investigate
the role of Sox1 in our model since it is very homolo-
gous to the induced pluripotent stem cell (iPS) regulator
Sox2, and has been shown to play a role in progression
of lung and nasopharyngeal cancer [19,20]. We also
chose to investigate bone marrow tyrosine kinase gene
in chromosome X protein (Bmx) since it has been
shown to regulate hematopoiesis [21] and play a role in
the regulation of prostate cancer [22]. However, from
our Oncomine analysis Bmx was not shown to signifi-
cantly affect prostate cancer metastasis (Figure 2).
Verification of methylation array data
To verify the results from our methylation specific pro-
moter tiling arrays, we performed methylation specific
PCR (MS-PCR) where primers were designed around
the probe sequences identified from the arrays. Both
Bmx and Sox1 were found to be methylated in the
Figure 1 Isolation and MeDIP analysis of invasive prostate cancer cells. Matrigel-coated 24-well inserts (8 μM pore size) and non-coated
control inserts purchased from BD Biosciences were used according to manufacturer’s instructions. A range of 70,000-100,000 cells was seeded
for the invasion. Cells were seeded in serum-free RPMI and migrated toward media specific for stem cells (termed SCM). For the isolation of
DNA from top “non-invading” and bottom “invading” cells, parallel invasion chambers were set up. For non-invading cells, the bottom of the
membrane was scrubbed with a cotton swab, and cells on top were harvested using 500 μL of trypsin incubated at 37°C for 5 minutes. To
obtain the invading cells, the top of the membrane was scrubbed with a cotton swab, and the membranes were placed at -80°C until DNA
extraction was performed or the cells were harvested with trypsin, as previously mentioned. DNA was extracted using a DNeasy kit (Qiagen),
where the cell-based protocol was used to isolate DNA for the top cells, while the tissue extraction method was used to isolate the invaded
cells from the previously stored membrane. Total genomic DNA was digested with MseI overnight, and methylated DNA was then collected
using MethylCollector kit (Active Motif). Input and methylated DNA was then amplified with 2 rounds of PCR and labeled with either Cy5 for
methylated or Cy3 for total DNA. The samples were combined and applied to Agilent’s Human Promoter Tiling Array for 40 hours at 65°C. The
arrays were then scanned with an Axon scanner (4000B) using GenePixPro version 6.1. The data were extracted using Agilent’s Feature Extraction
software 9.3.5.1, and differences in promoter methylation of genes in non-invasive and invasive cells were compared using Agilent’s ChIP
Analytics software version 4.0. Selected targets were then verified for methylation status using methylation-specific PCR, qRT-PCR and ICC.
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3A), representing the non-invasive phenotype. To deter-
mine if this pattern of methylation correlated with the
level of gene expression, real time quantitative PCR
(qRT-PCR) was performed. Significant differences in the
expression of Bmx and Sox1 were seen when comparing
the expression in non-invasive and invasive cell popula-
tions in both LNCaP and DU145 cell lines (Figure 3B)
(Two-way ANOVA; *compares non-invasive to parental
and ** compares invasive to parental, p < 0.05). To
further validate the results, immunocytochemistry (ICC)
was performed to analyze differences in protein expres-
sion between non-invasive and invasive cells. There is
significantly higher expression of activated BMX and
SOX1 in the invasive versus non-invasive cells (Figure
3C). Therefore, we validated the methylation and resul-
tant decreased expression of BMX and SOX1 in the
non-invasive cells.
Functional role of Bmx and Sox1 during invasion
To further determine the role of Bmx and Sox1 during
the process of invasion we performed the invasion assay
with DU145 cells stably infected with shRNAs directed
against Sox1or Bmx (Figure 4). A significant decrease in
expression of SOX1 and BMX following induction with
1 μg/mL of doxycycline (Dox) for 24 hours was first
verified using western blotting. Upon induction with
Dox, the shRNA is turned on and a downstream red
fluorescent protein (RFP) demonstrates efficiency of this
induction (Figure 4A). Densitometry analysis was per-
formed to compare expression of individual clones with
the NS cells, and no significant differences in protein
expression were seen using the non-silencing (NS) con-
trols (Figure 4B). In addition, SOX1 shRNA cells
demonstrated a significant decrease in proliferation
compared to either the parental cell line (total cells) or
the NS infected line (Figure 4C), as well as a significant
decrease in invasion toward SCM (Figure 4D) (p-value
< 0.05). However, there was not a significant difference
using the shBMX lines, except for a slight reduction in
invasion using clone #3. Interestingly, a small increase
in proliferation was seen with the shBMX clones (Figure
4C). Further promoter tiling array analysis using two
short term cultures primary prostate tumor cell lines,
PCSC1 and PCSC2, determined that Sox1, and not
Bmx, was methylated in the invasive population of cells
(Additional File 2, Table S2A and B). Overall, we
demonstrate that Sox1is differentially methylated within
the invasive CSC population and the shRNA studies
indicate it could be selectively targeted to block
invasion.
Table 1 Summary of genes methylated within the non-
invasive LNCaP and DU145 cell lines
Gene Agilent ID Location
ABCF3 A_17_P02824570 chr3:185384633-185384688
ACRC A_17_P11784482 chrX:70712439-70712498
ARHGEF9 A_17_P11762981 chrX:62889218-62889272
AVPR1A A_17_P08402446 chr12:61828587-61828646
BCL2A1 A_17_P09781583 chr15:78049283-78049342
BMX A_17_P11607973 chrX:15428990-15429037
CAPN6 A_17_P11887436 chrX:110391469-110391527
CNIH3 A_17_P00830574 chr1:222866130-222866189
DIO3 A_17_P09520078 chr14:101092190-101092234
DLGAP1 A_17_P10514555 chr18:3832861-3832920
DONSON A_17_P11359769 chr21:33880442-33880501
EXOC3L2 A_17_P17147769 chr19:50426839-50426891
GNB1 A_17_P00002239 chr1:1744644-1744703
GPR103 A_17_P03395862 chr4:122518949-122518996
GPR81 A_17_P08659974 chr12:121778515-121778572
GUCY2F A_17_P11879791 chrX:108613896-108613952
HRK A_17_P08637968 chr12:115801241-115801285
hsa-mir-346 A_17_P07370831 chr10:88012234-88012278
hsa-mir-507 A_17_P12010468 chrX:146120196-146120255
hsa-mir-542 A_17_P11969030 chrX:133503290-133503349
HTR2A A_17_P08830482 chr13:46365855-46365914
IRX3 A_17_P10024825 chr16:52875157-52875205
LOC339344 A_17_P10976156 chr19:51085104-51085163
MAGEA8 A_17_P12020625 chrX:148768376-148768435
MYH3 A_17_P10227610 chr17:10497672-10497716
NCAM1 A_17_P08036168 chr11:112332051-112332110
NR2E1 A_17_P04970834 chr6:108588654-108588713
NUP85 A_17_P10465401 chr17:70708211-70708270
PARVB A_17_P11521863 chr22:42723842-42723888
RAMP2 A_17_P10328303 chr17:38161563-38161609
RBBP8 A_17_P10568640 chr18:18762400-18762459
RPS4X A_17_P11786429 chrX:71410283-71410342
SCG3 A_17_P09654436 chr15:49755368-49755423
SCGB1A1 A_17_P07831562 chr11:61937609-61937653
SIGLEC1 A_17_P11026333 chr20:3615793-3615841
SIX1 A_17_P16707873 chr14:60183180-60183224
SLC5A1 A_17_P11476138 chr22:30766279-30766324
SOX1 A_17_P09141969 chr13:111764575-111764619
SPATA5L1 A_17_P09626282 chr15:43477779-43477838
TCF12 A_17_P09676944 chr15:54992977-54993036
TMEM46 A_17_P08732705 chr13:25520762-25520811
TNRC6A A_17_P09967235 chr16:24643725-24643784
VSIG1 A_17_P11874787 chrX:107171900-107171959
ZBTB16 A_17_P08041891 chr11:113430193-113430252
Genes methylated within the non-invasive population of LNCaP and DU145
cell lines. Once extracted from the Chip Analytics software, a list of genes
which were methylated in the non-invasive cells, yet not in the invasive
population was generated. The Agilent ID corresponds to the probe location
on the chromosome.
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2.35e-5 GNB1
6.18e-4 DONSON
8.65e-4 RBBP8
8.83e-4 SPATA5L1
0.005   LOC339344
0.006   SCG3
0.007   TMEM46
0.008   TNRC6A
0.013   ARHGEF9
0.024   SOX1
0.025   NUP85
0.027   SLC5A1
0.041   EXOC3L2
0.044   DIO3
0.044   RAMP2
0.096   SIX1
0.104   NCAM1
0.128   DLGAP1
0.134   TCF12
0.203   ABCF3
0.272   SIGLEC1
0.294   BMX
0.303   PARVB
0.355   MAGEA8
0.373   GUCY2F
0.443   HRT2A
0.499   AVPR1A
0.544   NR2E1
0.637   ACRC
0.568   RPSX4
0.738   ZBTB16
0.783   SGCB1A1
0.784   GPR81
0.824   VSIG1
0.939   BCL2A1
0.958   CAPN6
0.962   CNIH3
0.976   IRX3
0.999   MYH3
-   GPR103
Most Expressed Least Expressed
Not Expressed
1 Primary
2 Metastatic
Figure 2 Oncomine analysis of overlapping targets methylated in both LNCaP and DU145 cells. Isolated targets from the methylation arrays
overlapping in LNCaP and DU145 cells were analyzed in Oncomine 4.2 (Ann Arbor, MI). The heat map represents raw data from the Varambally
over-expression in prostate cancer analysis comparing primary tissue and metastatic tissue [17]. Expression is in terms of normalized over-
expression units. The P-value represents a student’s t-test comparing primary and metastatic expression and the gene ID is provided. Genes of
interest included Sox1 (p = 0.024) since it has high homology to the stem cell gene Sox2 and albeit demonstrating significance, Bmx (p = 0.294),
since it has previously been implicated in prostate cancer regulation.
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Page 8 of 17Role of SOX1 during differentiation
In addition to the method presented here, prostate TICs
(tumor initiating cells) can also be isolated by culturing
total cells in SCM where structures called prostato-
spheres are generated [18,23-25]. The prostatospheres
are multicellular globes that develop from cells that sur-
vive anchorage-independent conditions in vitro,a n da r e
frequently used when analyzing the ability of TICs to
self-renew or differentiate upon the addition of serum.
Using this assay as a model, a greater number of prosta-
tospheres were isolated from DU145 NS cells compared
to shSOX1 cells (Additional File 3, Figure S1A and B).
When invasive DU145 cells were isolated and cultured
in SCM, prostatospheres were maintained for up to 3
passages (Additional File 3, Figure S1C) and if these
cells were further cultured in the presence of 1% human
serum (Additional File 3, Figure S1C), the vector control
(NS) cells rapidly differentiated and proliferated, while
the shSOX1 cells did not (Additional File 3, Figure
S1D). These observations suggest that not only does
Sox1 play a role in regulating invasion, but it can also
regulate the maintenance of ‘stem-ness’ in culture.
Figure 3 Validation of methylated targets in LNcaP and DU145 cells. A) DNA was extracted using the DNeasy kit and total of 1 μg from
parental (total) LNCaP and DU145 cells was bisulfite modified using the EpiTect Bisulfite kit from Qiagen. MS-PCR was performed using Platinum
Taq Polymerase (Invitrogen) and 200 ng of either genomic of bisulfite treated DNA was used. The samples were visualized using a 1% agarose
gel and ethidium bromide. Both Sox1 and Bmx are methylated in the LNCaP and DU145 cell lines. B) Total RNA was isolated using TRIzol and
qRT-PCR analysis was performed using a StepOne Real-time PCR machine with TaqMan Gene Expression Assay reagents and probes. Isolation of
DNA and cDNA from non-invasive and invasive cells was carried out as previously described in materials and methods. Relative fold induction of
mRNA was compared between non-invasive and invasive cells using the Delta-Delta CT method of quantitation where the parental lines were
set at 1.0 as the control, and 18S rRNA was used as a loading control. Increased levels of both Sox1 and Bmx are seen in invasive LNCaP and
DU145 cells compared to the non-invasive and parental lines. Normal human prostate RNA was used as a control. A Two-way ANOVA with a
Bonferroni post-test was performed to compare groups and * represents a p-value of <0.05 comparing parental to non-invasive cells and
** comparing parental to invasive cells. C) Staining of invasive or non-invasive cells was performed directly on the Matrigel membrane. Cells
were incubated with either anti-pBMX antibody or SOX1 overnight and goat anti-rabbit Alexa-488 was added for 1 hour. Membranes were
mounted on glass slides with Vectashield containing DAPI and visualized with a Zeiss-510 L5 confocal microscope. Images were analyzed using
the Zeiss LSM5 Image Browser (20×) and further prepared in Adobe Photoshop CS. Increased levels of pBMX and SOX1 are seen in invasive cells
compared to the non-invasive cells on top of the membrane.
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differentially methylated genes within invasive sub-
populations of cells
Each data set of differentially methylated genes was then
extracted and uploaded to the Ingenuity server to identify
common gene pathways that are regulated during the
process of invasion. The most conserved functional path-
ways between the cell lines are cellular development, cell
growth and proliferation, as well as organismal develop-
ment, nervous system development and function, and tis-
sue development (Additional File 4, Table S3). The full
list from the Ingenuity pathway analysis is also included
(Additional File 5, Figure S2A and S2B). Additionally, the
IL-6 signaling pathway involving STAT3 had a significant
number of contributing methylated genes, a pathway
recently found to play a significant role in cancer stem
cell regulation [26-34] (Additional File 6, Figure S3A).
Inhibitor studies further determine the role of IL-6/STAT3
pathway in invasion
Based on the information generated from Ingenuity, we
chose to determine how the IL-6 pathway might be regu-
lating this process of invasion. A number of inhibitors of
downstream targets of IL-6 regulation were tested for
their ability to block invasion toward SCM. We included
a neutralizing antibody to interleukin-6 (IL-6) to test
Figure 4 Functional Role of SOX1 during invasion. A) The Trans-Lentiviral pTRIPZ system from Open Biosystems was used to introduce shRNA
against BMX, SOX1 or a non-silencing control vector in DU145 cells. The cells were selected for 2 weeks in 1 μg/mL of puromycin and single cell
clones were generated. To induce expression of the shRNA 1 μg/mL of doxycycline was added. The plasmid is designed to have a TET inducible
TurboRFP upstream of the shRNA and they should appear red upon successful infection. B) Lowered expression was confirmed using Western
blotting. Follow up experiments were conducted using BMX clone 3 and 5 and SOX1 clone 7 and 8 since they demonstrated the most significant
decrease in protein expression. Fold changes represent samples normalized to actin and the control level of expression. C) Proliferation assays were
conduced using Cell Titer-Glo kit and assayed on Day 1, 3, 5 and 7. More proliferation is indicated by an increase in relative luciferase units (RLUs).
*denotes statistical significant p < 0.05 compared to vector transfected cells. A significant decrease was observed in shSOX1 #7 cells compared to
vector transfected cells, and a significant increase was observed in shBMX #5 cell line. D) Matrigel invasion assays were conducted for 24 hours
toward SCM. Top cells were removed and bottom cells were stained with the Diff-Quick staining kit from Dade Behring. Cells were counted using 4
independent fields per sample and 2 chambers were used per cell line. *denotes statistical significance p < 0.05 compared to vector transfected
cells. Both shSOX #7 and #8 demonstrated significant decreases in invasion toward SCM compared to vector transfected cells.
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Page 10 of 17what effect this may have upstream. Downstream of the
receptor, the following inhibitors were used; the PI3K
inhibitor LY294002, small molecular inhibitor of MEK
called U0126 (thus downstream inhibition of extracellu-
lar-related kinase (ERK1 and ERK2) mediated responses),
a small molecule inhibitor of JAK (Janus Kinase) called
AG490 and an inhibitor of its partner signal transducers
and activators of transcription-3 (STAT3) called Stattic
(Figure 5A). Additionally, we tested the ability of the Tec
kinase family inhibitor LFM-A13 based on the potential
involvement of BMX during invasion (Figure 5A). The
inhibitors which demonstrated the greatest effect at
blocking invasion included Stattic, LY294002, and LFM-
A13 (Figure 5A). However, a proliferation assay deter-
mined that Stattic could be preventing invasion because
it was either cytotoxic to the cells or causing them to
undergo apoptosis (Additional File 6, Figure S3B). To
eliminate this possibility, viable cells were isolated after
treating the DU145 cell line with Stattic for 24 hours
(data not shown). These cells, although viable as deter-
mined by trypan blue staining, were still unable to invade.
Direct interaction between the differentially methylated
SOX1 and STAT3
Since inhibition of STAT3 demonstrated such a pro-
found effect on invasion toward SCM, we questioned its
involvement with the epigenetically regulated targets.
Although we did not observe methylation of Stat3 itself,
in both cell lines, the mRNA expression of Stat3 was
increased (p-value < 0.03) when comparing invasive cells
to their non-invasive counterpart (Figure 5B). Protein
expression of pSTAT3 was also found to be increased in
the invasive cells (Figure 5C). Since both SOX1 and
STAT3 are known to act as transcriptional activators
after forming protein complexes with other proteins
[35-40], and BMX is known to activate STAT3 itself [40],
we determined whether STAT3 directly interacts with
either SOX1 or BMX. An interaction between SOX1 and
STAT3 was observed (Figure 5D), however not between
STAT3 and BMX (Figure 5D). In addition, a significant
decrease in the expression of activated pSTAT3 was seen
in both sub-cellular fractions of the BMX and SOX1
shRNA infected cells (Figure 5E). However, there was no
change in total expression of STAT3. Additionally, a sig-
nificant decrease in STAT3 DNA binding activity was
observed in both BMX and SOX1 shRNA infected cells
(Figure 5F). Overall, we see an interaction between SOX1
and STAT3, and upon loss of either BMX1 or SOX1
expression we observe a loss of STAT3 activation.
To further elucidate the connection between the
SOX1 and STAT3, a decrease in the STAT3 target gene
Mcl-1 and Stat3 itself were observed by qRT-PCR in
shSOX1 clone #7 cells (Figure 6A). However, no change
was observed for the STAT3 targets genes Survivin or
Myc (Figure 6A). Finally, since prostatospheres are also
a model for generating aggressive populations of cells in
culture, we generated them from LNCaP cells and asked
if STAT3 genes were affected. qRT-PCR analysis was
performed and compared to adherent LNCaP cells,
expression of Stat3 and Stat3 target genes Mcl-1, Myc,
and Survivin were increased as well as Bmx and Sox1
(Figure 6B).
In order to determine what might be regulating the
increased expression of Stat3 and Sox1,t r a n s c r i p t i o n
factor binding sites were analyzed using Genomatix soft-
ware. In both the Stat3 and Sox1 promoters there are a
number of overlapping binding sites for transcription
factors with a significant matrix value such as GATA-
binding factors, RNA polymerase II transcription factor
IIB (TFIIB), NeuroD/Beta2, TALE homeodomain class
recognizing TG motifs, TCF11 transcription factor
otherwise known as Nrf2, Nkx homeodomain factors,
and finally the Zinc finger transcription factor RU49
also called Zipro1 (Additional File 7, Table S4). With
this information, we can begin to understand why the
methylation of Sox1 could serve as a master regulator of
CSC invasion, thereby controlling its potential to
undergo EMT and further metastasize.
Additional analysis using the GEO database deter-
mined that both Sox1 and Stat3 are expressed at higher
levels in metastatic prostate cancer tissues and not Bmx
(Figure 6C and 6D). Overall, we demonstrate that SOX1
is an epigenetically regulated target involved in the pro-
gression of prostate cancer, and is involved in signaling
via the STAT3 pathway.
Discussion
The process of epigenetic regulation by DNA methyla-
tion involves covalent modification of cytosine nucleo-
tides at the C5 position in specific areas of CpG
dinucleotides. The majority of methylated CpG dinucleo-
tides are present in heterochromatic regions, and thus
are unexpressed in the genome [41]. The process of
methylation in mammals evolved as a method of silen-
cing genes when their expression is not required. For
example, the process of genomic imprinting involves
DNA methylation where one allele of a gene, either
maternal or paternal, is silenced [42]. This process only
affects a few hundred genes within the genome, most of
which encode for genes that regulate embryonic and neo-
natal growth [43]. Likewise, a number of CpG islands on
one X chromosome are methylated during a process
called X-chromosome inactivation [44]. This process
ensures an equal amount of gene expression between
males and females.
Using this model of invasion, we currently have devel-
oped a method to analyze differences in global CpG
promoter methylation between total prostate cancer
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Page 11 of 17Figure 5 Direct interaction between SOX1 and STAT3. A) Matrigel invasion assays were performed for 24 hours toward SCM using DU145
cells in the presence of the anti-IL-6, the PI3K inhibitor LY294002, a small molecular inhibitor of MEK called U0126 (thus downstream inhibition
of extracellular-related kinase (ERK1 and ERK2) mediated responses), a small molecule inhibitor JAK called AG490 (Janus Kinase) and an inhibitor
of its partner signal transducers and activators of transcription-3 (STAT3) called Static or the Tec kinase family inhibitor LFM-A13.Significant
differences were observed between control cells and those cells treated with U0126, Stattic, LY294002 and LFM-A13. B) qRT-PCR analysis was
performed as mentioned in Figure 3. *denotes statistical significant p < 0.05 compared to the non-invasive cells. Increased levels of Stat3 are
seen invasive LNCaP and DU145 cells compared to the parental lines. C) Staining of pSTAT3 in invasive or non-invasive DU145 cells was
performed directly on the Matrigel membrane and carried out as previously described in Figure 3. D) DU145 lysates were incubated with either
SOX1, STAT3 or BMX overnight at 4°C with rotation. Samples were then incubated with Protein A-agarose beads to isolate complexes.
Membranes were then incubated overnight at 4°C using primary antibodies for STAT3 or SOX1. The membrane was developed using the
Odyssey from Licor. Protein loading was normalized using actin as a control. E) Western blotting for STAT3 and pSTAT3 in sub-cellular protein
extracts from DU145, NS, shBMX#3 or shSOX1#8. F) STAT3 EMSA: Each lane contains WT-IR STAT3 oligos. Lane 1-3 DU145, 4 and 5 NS, 6 and 7
shBMX#3, 8 and 9 shSOX1 #8 and 10 contains no protein. Lane 2 contains excess MU-IR STAT3 and lanes 3, 5, 7 and 9 contain excess unlabeled
WT probe. Supershifited samples appear below and only contain WT-IR STAT3.
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Page 12 of 17cells and their invasive population using promoter tiling
arrays from Agilent. We identified a small subset of
genes which were found to be differentially methylated
between non-invasive and invasive LNCaP and DU145
cell lines. The results were highly intriguing because the
majority of the genes normally function during human
development (Additional File 4, Table S3). Based on
previous data, these invasive cells demonstrated charac-
teristics of true cancer stem cells (CSCs) [7]. It is
b e c o m i n gm o r ee v i d e n tt h a tC S C sa r en o tg o v e r n e db y
the same type of genetic regulation as normal stem
cells, and arguably may be an epithelial cell that has up-
regulated pathways that have been previously observed
in true stem cells. To determine the epigenetic profile of
these invasive prostate cancer cells and putative TICs,
we determined which genes are differentially methylated.
The appearance of Sox1 as one epigenetically regu-
lated target presented the most interesting finding of
this investigation. SOX proteins are transcription factors
that are key regulators of determining neuronal cell fate,
not only mammals, but also in Drosophila, Xenopus, and
avian models [36]. Recently, much attention has been
focused on these transcription factors since ectopic
expression of Sox2 along with Oct3/4, Klf4 and Myc
have been shown to reprogram murine fibroblasts to
pluripotency, which in turn yields induced pluripotent
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Figure 6 Inhibitor studies further determine that the IL-6/STAT3 pathway is involved in invasion. A) qRT-PCR demonstrating decreased
expression of Stat3 in DU145 shSOX1 clone #7 cells and Mcl-1,aStat3 target gene. No change was observed in Myc or Survivin. *denotes
statistical significant p < 0.05 compared to the vector transfected line. B) Prostatospheres were generated by culturing LNCaP cells in SCM+KO
for 7 days and qRT-PCR analysis was performed. Compared to adherent LNCaP cells, expression of Bmx, Sox1 Mcl-1, Myc, Survivin, and Stat3 was
significantly increased in the stem-like prostatospheres. *denotes statistical significant p < 0.001 compared to the adherent cells. C) Correlation of
Sox1 and Stat3 was analyzed in Oncomine 4.2 (Ann Arbor, MI). The heat map represents raw data from the Varambally over-expression in
prostate cancer analysis comparing primary tissue and metastatic tissue. Expression is in terms of normalized over-expression units. The P-value
represents a student’s t-test comparing primary and metastatic expression. D) Using the GEO database, expression of Sox1 and Bmx were
compared between benign, primary or metastatic prostate tissue and significant differences were observed in Sox1. For Stat3, a comparison
between Prostate Intraepithelial Neoplasia (PIN) and invasive prostate tumor tissue yield a significant difference in expression. *denotes statistical
significant p < 0.05 compared to either benign samples or PIN.
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Page 13 of 17stem (iPS) cells [45]. In our model, when expression of
SOX1 was decreased in DU145 cells using shRNA, there
was a significant reduction in invasion toward our stem
cell media termed SCM (Figure 4D). Although SOX1
has yet to be implicated as a regulator of aggression in
prostate cancer, it has been implicated as a marker of
CSCs in breast cancer. Using either CD44
+/CD24
- or
CD133
+ cells isolated from Brca1-deficient mouse mam-
mary tumors, expression of Sox1 was found to be signif-
icantly higher in these cells when compared to their
counterparts [46]. In fact, expression of Sox1 was found
to be 19.2-fold higher in CD44
+/CD24
- compared to
CD44
-/CD24
+ cells, which represented the greatest
change in any gene from this analysis [46].
The appearance of Bmx (also referred to as Etk)a sa
differentially methylated target was also interesting, yet
not surprising, since this protein is a well-known regula-
tor of prostate cancer. BMX is a family member of the
Tec family of non-receptor tyrosine kinases that are pre-
dominately expressed in cells of hematopoietic origin,
yet recently has also been shown to be expressed in
arterial endothelium and a variety of epithelial cells
[21,39,47,48]. Although BMX has a role in the formation
of leukemia [21,49], our research is the first to demon-
strate that BMX may play a significant role in the regu-
lation of prostate cancer invasion and TICs. Although
our shRNA studies against BMX did not demonstrate
significant differences in invasion toward SCM, we were
able to inhibit invasion of DU145 cells using the Tec
family kinase inhibitor LFM-A13 without affecting nor-
mal cell proliferation (Additional File 6, Figure S3B),
suggesting that this family of kinases may be indeed
involved in metastasis.
After uploading our extensive list of differently methy-
lated genes into the Ingenuity pathway analysis software,
we observed that a number of the genes were members
of the IL-6/STAT3 pathway. We tested a number of
inhibitors of the IL-6 pathway for their ability to block
invasion toward SCM. Small and non-significant effects
of invasion were seen when inhibitors for MEK and JAK
pathways, as well as a neutralizing antibody to IL-6 itself
(Figure 5A). However, significant effects were seen using
a PI3K inhibitor and a STAT3 inhibitor (Figure 5A).
T h er o l eo fP I 3 Ks i g n a l i n gi np r o s t a t eC S Cr e g u l a t i o n
has been characterized, thus this observation is not too
surprising [50]. The most pronounced effect, however,
was observed with the STAT3 inhibitor Stattic. This
drug inhibits binding of a phosphotyrosine-containing
peptide derived from the gp130 receptor to the STAT3
SH2 domain with IC50 value of 5.1 ± 0.8 μMa f t e r1h r
of incubation at 37°C [51]. The role of STAT3 in cancer
progression has been known for sometime [52-56], and
its role in CSC regulation has only recently been investi-
gated. Higher levels of STAT3 have been demonstrated
in CSCs isolated from liver, bone, cervical and brain
cancers [26,27,29,57-59], and furthermore treatment of
putative glioblastoma stem cells (GBM-SC) with Stattic
results in a dramatic reduction in their formation [27].
Although the Stat3 gene itself was not methylated in
any of our studies, qRT-PCR analysis demonstrated that
compared to non-invasive cells, the invasive cells had a
significant increase in expression of Stat3 (Figure 5B)
and ICC detected an increase in active protein as well
(Figure 5C). However, as seen in Figure S3B, there was
a significant reduction in cell proliferation with Stattic
treatment. To determine if this was the reason why we
observed such a significant reduction in invasion, we
took the remaining cells which survived treatment and
further placed them through an invasion assay. The cells
were unable to invade toward SCM, indicating that the
cells resistant to Stattic-induced apoptosis were still sen-
sitive at inhibiting invasion by lowering STAT3 (data
not shown). A similar result was observed in the GBM-
SCs, since different isolates of the cells responded differ-
ently to treatment with Stattic. The authors concluded
that GBM-SCs derived in serum respond to Stattic by
undergoing apoptosis, however in those derived using
stem cell media they do not [27]. They state that this
could be a result of certain GBM-SC lines being more
differentiated, and are thus more sensitive to STAT3
inhibition.
Since inhibition of SOX1 with shRNA and BMX ulti-
mately with LFM-A13 (data not shown, but LFM-A13
inhibited IL-6 mediated activation of BMX in LNCaP
cells) decreased invasion toward SCM, we sought to
determine if an interaction might be occurring between
these differentially methylated genes and STAT3. To
test this, an IP was performed to see if either BMX or
SOX1 directly interact with STAT3. We found that only
SOX1 could directly interact with STAT3 and not BMX
(Figure 5D), and this interaction occurs in both the
cytoplasm and the nucleus. Int h e s es u b - c e l l u l a rf r a c -
tions, we still see an association between SOX1 and
STAT3 in shSOX1 cells since expression of the protein
was not fully ablated (Figure 4B). Interestingly,
decreased expression of either BMX or SOX1 does
result in significantly less active STAT3 (Figure 5E) and
a decrease in its DNA binding activity (Figure 5F). This
observation is not too surprising since BMX has been
shown to regulate such cellular processes as differentia-
tion, motility, invasion, apoptosis, and more recently,
when inhibited, a delay in tumor growth [22,60-66].
Specifically, within the prostate, BMX is up-regulated in
tumors from both mouse and human specimens com-
pared to benign tissues, and when over-expressed in cell
lines, led to an increase in proliferation and elevated
levels of AKT and STAT3 [22]. Albeit having a role in
the formation of leukemia [21,49], our research is the
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Page 14 of 17first to demonstrate that BMX may play a significant
role in the regulation of prostate CSCs.
Both STAT3 and SOX1 are transcription factors that
regulate cell fate and differentiation; however a direct
interaction between these proteins has never been identi-
fied. Future studies will be needed to determine what pro-
tein domains of each molecule are important for this
interaction, as well as which promoters these transcription
factors are regulating. However, the Oncomine and GEO
data further support the observation that expression of
both Sox1 and Stat3 are key genes regulating the progres-
sion of prostate cancer (Figure 6C and 6D). Regulation of
Sox1 and Stat3 expression could occur coordinately since
within their promoters they both contain transcription fac-
tor binding sites for NeuroD, TALE containing proteins,
TCF11, and Nkxs (Additional File 7, Table S4). The TCF
family of transcription factors regulates many patterns of
development and activation of the TCF/LEF promoters.
Recently, the Wnt proteins have been shown to regulate
the ‘stemness’ of CSCs [67-70]. Additionally, expression of
Nkx factors are required for neuronal cell fate, and inter-
estingly, Nkx2.2, Nkx6.1 and Irx3, a NKX target, are also
methylated in our study (Table 1) [71].
Conclusions
Overall, our data demonstrates that Sox1 is methylated
in two prostate cancer cell lines, LNCaP and DU145,
and two short-term primary prostate cancer cultures,
PCSC1 and PCSC2, yet not methylated in the invasive
compartment of these cells. The expression of Sox1 was
f o u n dt ob ec o r r e l a t e dw ith increased levels of Stat3 in
our invasive cells, and to directly interact with the pro-
tein product as well. Finally, both Sox1 and Stat3 were
found to have increased expression in relation to the
progression of prostate cancer in humans. Using our in
vitro method to investigate invasion we can begin to
understand which genes are epigenetically regulated in
the invasive putative CSC population. The process of
epigenetic regulation is complex, but we have begun to
unravel it in these invasive cells from the prostate.
Additional material
Additional file 1: Table S1: Total methylated gene lists generated
by Chip Analytics software. A) LNCaP B) DU145. Data represents those
changes with a p-value ≤0.05 using nearest neighbor analysis. Genes are
listed in alphabetical order according to their gene name.
Additional file 2: Table S2: Total methylated gene lists generated
by Chip Analytics software. A) PCSC1 B) PCSC2. Data represents those
changes with a p-value ≤ 0.05 using nearest neighbor analysis. Genes are
listed in alphabetical order according to their gene name.
Additional file 3: Figure S1: Prostatosphere formation and
differentiation of DU145 and shSOX1 #7 cells. DU145 cells were
seeded 1000 cells per mL in replacement media SCM and supplemented
with B27 in non-adherent 6 well plates coated with Hydrogel. The
prostatospheres were generated for 5-7 days and then quantified. A)
Comparison of DU145 spheres and those from clone #7 using the shRNA
against SOX1. B) Number of spheres generated from DU145, NS and
shSOX1 clone #7 cell lines. C) Ability of DU145 NS invasive cells to
differentiate after addition of 1% human serum for 96 hours in culture
and morphologically resemble DU145 NS cells. D) Comparison of
differentiation potential of invasive cells isolated from DU145, NS and
shSOX1 #7 cell lines.
Additional file 4: Table S3: Summary of significant functional gene
pathways generated by Ingenuity software analysis for genes not
methylated within the invasive cells.
Additional file 5: Figure S2: Ingenuity analysis of methylation data
demonstrating significant changes in functional gene pathways. A)
DU145 B) LNCaP.
Additional file 6: Figure S3: A) Ingenuity analysis of methylation data
demonstrating significant changes in canonical gene pathways in LNCaP.
B) Proliferation assay for 24 hours using inhibitors from Figure 5A
measured using CelTiter-Glo. Significant differences were seen between
control cells and cells treated with Stattic. *denotes statistical significant
p < 0.05 compared to the adherent cells.
Additional file 7: Table S4: Predicted transcription factor (TF)
binding sites common to both the sox1 and stat3 promoters.T h e
potential TF factors sites were generated using the Genomatix software
with full length promoter sequences for both genes.
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